Clonazepam (Epilepsy) updated on 02-10-2025

Perinatal death

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5924
R15058		 Artama (Epilepsy) (Controls exposed to Lamotrigine, sick), 2013 Perinatal death (stillbirth or early neonatal death (0–6 days of age)) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 12.78 [0.24;669.58] C
excluded (control group) 		0/14   0/173 0 14
ref
S5905
R14850		 Artama (Epilepsy) (Controls unexposed, disease free), 2013 Perinatal death (stillbirth or early neonatal death (0–6 days of age)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: No 7.51 [0.45;126.34] C
excluded (control group) 		0/14   3,543/721,948 3,543 14
ref
S5916
R14969		 Artama (Epilepsy) (Controls unexposed, sick), 2013 Perinatal death (stillbirth or early neonatal death (0–6 days of age)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No 6.31 [0.35;113.26] C 0/14   10/1,800 10 14
ref
S328
R20084		 Canger (Epilepsy), 1999 Perinatal deaths (NOS) 1st trimester prospective cohort unexposed, sick Adjustment: No 4.45 [0.08;250.02] C 0/6   0/25 0 6
ref
Total 2 studies 5.61 [0.54;58.60] 10 20
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Artama (Epilepsy) (Controls unexposed, sick), 2013Artama, 2013 1 6.31[0.35; 113.26]101466%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Canger (Epilepsy), 1999Canger, 1999 2 4.45[0.08; 250.02]0634%ROB confusion: criticalROB selection: moderateROB classification: lowROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 5.61[0.54; 58.60]10200.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Epilepsy) (Controls unexposed, sick; 2: Epilepsy;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.61[0.54; 58.60]10200%NAArtama (Epilepsy) (Controls unexposed, sick), 2013 Canger (Epilepsy), 1999 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 5.61[0.54; 58.60]10200%NAArtama (Epilepsy) (Controls unexposed, sick), 2013 Canger (Epilepsy), 1999 2 Tags Adjustment   - No  - No 5.61[0.54; 58.60]10200%NAArtama (Epilepsy) (Controls unexposed, sick), 2013 Canger (Epilepsy), 1999 2 All studiesAll studies 5.61[0.54; 58.60]10200%NAArtama (Epilepsy) (Controls unexposed, sick), 2013 Canger (Epilepsy), 1999 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 5924, 5905

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 7.51[0.45; 126.34]3,54314 -NAArtama (Epilepsy) (Controls unexposed, disease free), 2013 1 unexposed, sick controlsunexposed, sick controls 5.61[0.54; 58.60]10200%NAArtama (Epilepsy) (Controls unexposed, sick), 2013 Canger (Epilepsy), 1999 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale12.78[0.24; 669.58]-14 -NAArtama (Epilepsy) (Controls exposed to Lamotrigine, sick), 2013 10.510.01.0